| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2021 | Blagoev KB, Iordanov R, Zhou M, Fojo T, Bates SE. Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. Oncotarget. 12: 15-21. PMID 33456710 DOI: 10.18632/oncotarget.27855 | 0.303 | |||
| 2020 | Chen KG, Duran GE, Mogul MJ, Wang YC, Ross KL, Jaffrézou JP, Huff LM, Johnson KR, Fojo T, Lacayo NJ, Sikic BI. Genomic stability at the coding regions of the multidrug transporter gene : insights into the development of alternative drug resistance mechanisms in human leukemia cells. Cancer Drug Resistance (Alhambra, Calif.). 3: 959-979. PMID 34541464 DOI: 10.20517/cdr.2020.51 | 0.488 | |||
| 2020 | Laderian B, Zhou M, Fojo T. Distribution of cancer genes in human chromosomes. Seminars in Oncology. PMID 32771229 DOI: 10.1053/J.Seminoncol.2020.05.011 | 0.311 | |||
| 2020 | Laderian B, Mundi P, Fojo T, Bates S. Emerging Therapeutic Implications of STK11 Mutation: Case Series. The Oncologist. PMID 32396674 DOI: 10.1634/Theoncologist.2019-0846 | 0.342 | |||
| 2019 | Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park YA, Anderson CB, Hsu TM, Langhoff E, McWilliams G, Drake CG, Simon R, Bates SE, Fojo T. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Seminars in Oncology. PMID 31757478 DOI: 10.1053/J.Seminoncol.2019.11.004 | 0.31 | |||
| 2019 | Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology. PMID 30738604 DOI: 10.1053/J.Seminoncol.2019.01.002 | 0.345 | |||
| 2018 | Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, et al. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute. PMID 30239887 DOI: 10.1093/Jnci/Djy133 | 0.31 | |||
| 2018 | Jawed I, Velarde M, Därr R, Wolf KI, Adams K, Venkatesan AM, Balasubramaniam S, Poruchynsky MS, Reynolds JC, Pacak K, Fojo T. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. Cellular and Molecular Neurobiology. PMID 29623478 DOI: 10.1007/S10571-018-0579-4 | 0.347 | |||
| 2018 | Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs. PMID 29420340 DOI: 10.1097/Cad.0000000000000596 | 0.362 | |||
| 2017 | Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nature Reviews. Clinical Oncology. PMID 29255239 DOI: 10.1038/Nrclinonc.2017.186 | 0.344 | |||
| 2017 | Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, ... ... Fojo T, et al. Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET. Oncotarget. 8: 73387-73406. PMID 29088715 DOI: 10.18632/Oncotarget.19945 | 0.324 | |||
| 2017 | Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. Plos One. 12: e0175484. PMID 28981524 DOI: 10.1371/Journal.Pone.0175484 | 0.38 | |||
| 2017 | Enzler T, Fojo T. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Seminars in Oncology. 44: 141-156. PMID 28923213 DOI: 10.1053/J.Seminoncol.2017.07.001 | 0.304 | |||
| 2017 | Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. The Oncologist. PMID 28679644 DOI: 10.1634/Theoncologist.2017-0211 | 0.325 | |||
| 2017 | Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28453615 DOI: 10.1093/Annonc/Mdx110 | 0.337 | |||
| 2016 | Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, ... Fojo T, et al. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. The Lancet. Oncology. PMID 27979599 DOI: 10.1016/S1470-2045(16)30633-7 | 0.333 | |||
| 2016 | Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. The Lancet. Oncology. 17: e81-6. PMID 26868357 DOI: 10.1016/S1470-2045(15)00620-8 | 0.349 | |||
| 2015 | Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. Jama Oncology. PMID 26181239 DOI: 10.1001/Jamaoncol.2015.1790 | 0.329 | |||
| 2015 | Basseville A, Bates S, Fojo T. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. Nature Reviews. Clinical Oncology. 12: 442-4. PMID 26169922 DOI: 10.1038/Nrclinonc.2015.125 | 0.335 | |||
| 2015 | Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. The Oncologist. 20: 725-6. PMID 26040622 DOI: 10.1634/Theoncologist.2015-0104 | 0.361 | |||
| 2015 | Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 16: 1014-8. PMID 26016850 DOI: 10.1080/15384047.2015.1046650 | 0.386 | |||
| 2015 | Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, ... ... Fojo T, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. British Journal of Haematology. 170: 96-109. PMID 25891346 DOI: 10.1111/Bjh.13400 | 0.367 | |||
| 2015 | Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. The Oncologist. 20: 400-10. PMID 25795635 DOI: 10.1634/Theoncologist.2014-0154 | 0.337 | |||
| 2015 | Burotto Pichun ME, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, Pacak K, Fojo T. Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P/PG): Preliminary results. Journal of Clinical Oncology. 33: 457-457. DOI: 10.1200/Jco.2015.33.7_Suppl.457 | 0.365 | |||
| 2015 | O'Sullivan CC, Lindenberg M, Bryla C, Davarpanah N, Peer C, Patronas N, Amiri-Kordestani L, Balasubramaniam S, Fojo T, Figg WD, Choyke P. Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B43 | 0.338 | |||
| 2014 | Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers. Cancer Research. 74: 4653-62. PMID 25183789 DOI: 10.1158/0008-5472.Can-14-0420 | 0.398 | |||
| 2014 | Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. Plos One. 9: e96316. PMID 24796484 DOI: 10.1371/Journal.Pone.0096316 | 0.335 | |||
| 2014 | Poruchynsky MS, Komlodi-Pasztor E, Wilkerson J, Trostel S, Burroto-Pichun M, Fojo T. Abstract LB-106: Microtubule-targeting agents (MTAs) disrupt intracellular trafficking of DNA repair proteins and augment the toxicity of DNA damaging agents (DDAs) Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-106 | 0.318 | |||
| 2013 | Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4499-507. PMID 23757352 DOI: 10.1158/1078-0432.Ccr-13-0095 | 0.362 | |||
| 2013 | Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3600-4. PMID 23650428 DOI: 10.1200/Jco.2013.49.1845 | 0.304 | |||
| 2013 | Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discovery. 3: 20-3. PMID 23319766 DOI: 10.1158/2159-8290.Cd-12-0514 | 0.365 | |||
| 2013 | Singh NK, Kim JW, Heery CR, Dahut WL, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo T, Arlen PM, Gulley JL, Madan RA. A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. Journal of Clinical Oncology. 31: TPS5104-TPS5104. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps5104 | 0.358 | |||
| 2013 | Wilkerson J, Bates SE, Stein WD, Fojo T. Using a program that computes tumor decay (d) and regrowth (g) rates and the fraction (Φ) of tumor killed to assist in clinical trials and improve patient survival. Journal of Clinical Oncology. 31: e22213-e22213. DOI: 10.1200/Jco.2013.31.15_Suppl.E22213 | 0.363 | |||
| 2013 | Burotto Pichun ME, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo T. Continuation of sunitinib following RECIST progression on first-line sunitinib. Journal of Clinical Oncology. 31: 4585-4585. DOI: 10.1200/Jco.2013.31.15_Suppl.4585 | 0.321 | |||
| 2013 | Stein WD, Wilkerson J, Manasanch E, Zhuang SH, Bates SE, Fojo T. Abstract 5152: Estimating the fraction of a tumor that is killed by a drug. Cancer Research. 73: 5152-5152. DOI: 10.1158/1538-7445.Am2013-5152 | 0.332 | |||
| 2013 | Amiri-Kordestani L, Mena E, Lindenberg M, Kurdziel K, Choyke P, Patronas N, Frye R, Lin N, Bala S, Fojo T, Bates S. Abstract P4-01-09: 18F-FLT-PET/CT for the prediction of response to ANG-1005 therapy in patients with brain metastases from breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-09 | 0.314 | |||
| 2012 | Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, ... ... Fojo T, et al. Combination chemotherapy in advanced adrenocortical carcinoma. The New England Journal of Medicine. 366: 2189-97. PMID 22551107 DOI: 10.1056/Nejmoa1200966 | 0.329 | |||
| 2012 | Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. The Oncologist. 17: 512. PMID 22416063 DOI: 10.1634/Theoncologist.2012-0080 | 0.358 | |||
| 2012 | Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle (Georgetown, Tex.). 11: 963-73. PMID 22333583 DOI: 10.4161/Cc.11.5.19447 | 0.378 | |||
| 2012 | Fojo T, Bates S, Chabner BA. Editor's Note ...Clinical Trial Reports: A New Section. The Oncologist. 17: 11-2. PMID 22286772 DOI: 10.1634/Theoncologist.2012-0040 | 0.305 | |||
| 2012 | Stein WD, Wilkerson J, Adesunloye B, Madan R, Bates SE, Wells S, Dahut W, Ning Y, Zhuang SH, Motzer RJ, Fojo T. Abstract 765: Growth rates of tumors with numerous histologies remain constant while patients are on therapy Cancer Research. 72: 765-765. DOI: 10.1158/1538-7445.Am2012-765 | 0.343 | |||
| 2011 | Fojo T, Amiri-Kordestani L, Bates SE. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. Journal of the National Cancer Institute. 103: 1738-40. PMID 22045362 DOI: 10.1093/Jnci/Djr386 | 0.366 | |||
| 2011 | Sackett DL, Fojo T. Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces. Cell Cycle (Georgetown, Tex.). 10: 3233-4. PMID 21946521 DOI: 10.4161/Cc.10.19.17126 | 0.354 | |||
| 2011 | Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nature Reviews. Clinical Oncology. 8: 244-50. PMID 21283127 DOI: 10.1038/Nrclinonc.2010.228 | 0.345 | |||
| 2011 | Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 907-17. PMID 21106727 DOI: 10.1200/Jco.2012.30.5_Suppl.133 | 0.309 | |||
| 2011 | Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 569-80. PMID 21081657 DOI: 10.1158/1078-0432.Ccr-10-1725 | 0.354 | |||
| 2011 | Poruchynsky MS, Gramza AW, Wells SA, Fojo T. Abstract 4547: Treatment of human medullary thyroid carcinoma (MTC) with either proteasome (Pr) or histone deacetylase (HDAC) inhibitors leads to a fall in RET mRNA levels and, in turn, a decrease in RET protein expression providing alternate strategies to reduce RET expression in a tyrosine-kinase driven disease Cancer Research. 71: 4547-4547. DOI: 10.1158/1538-7445.Am2011-4547 | 0.35 | |||
| 2010 | Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5972-80. PMID 21169250 DOI: 10.1158/1078-0432.Ccr-10-1277 | 0.35 | |||
| 2010 | Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Seminars in Oncology. 37: 619-26. PMID 21167380 DOI: 10.1053/J.Seminoncol.2010.10.011 | 0.32 | |||
| 2010 | Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. The Oncologist. 15: 969-75. PMID 20798195 DOI: 10.1634/Theoncologist.2010-0129 | 0.33 | |||
| 2010 | Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Research. 70: 5870-9. PMID 20587529 DOI: 10.1158/0008-5472.Can-09-4281 | 0.344 | |||
| 2010 | Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1634-41. PMID 20179242 DOI: 10.1158/1078-0432.Ccr-09-0379 | 0.325 | |||
| 2010 | Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. British Journal of Haematology. 148: 256-67. PMID 19874311 DOI: 10.1111/J.1365-2141.2009.07954.X | 0.336 | |||
| 2010 | Kelly RJ, Robey R, Draper D, Chen C, Venkatesan AM, Figg WD, Gardner E, Piekarz R, Balis F, Fojo T, Bates SE. Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Cancer Research. 70: 3527-3527. DOI: 10.1158/1538-7445.Am10-3527 | 0.395 | |||
| 2010 | Komlodi-Pasztor EM, Murphy R, Wilkerson J, Fojo T. Abstract 2554: Copper transporter 2 (CTR2) is able to transport cisplatin and/or oxaliplatin in drug-resistant cell lines Cancer Research. 70: 2554-2554. DOI: 10.1158/1538-7445.Am10-2554 | 0.345 | |||
| 2009 | Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer Journal (Sudbury, Mass.). 15: 379-85. PMID 19826357 DOI: 10.1097/Ppo.0B013E3181Bef8Cd | 0.345 | |||
| 2009 | Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer Journal (Sudbury, Mass.). 15: 366-73. PMID 19826355 DOI: 10.1097/Ppo.0B013E3181B9D37B | 0.329 | |||
| 2009 | Fojo T. From the guest editor: monitoring of therapeutic response to cancer treatment. Cancer Journal (Sudbury, Mass.). 15: 352-3. PMID 19826352 DOI: 10.1097/Ppo.0B013E3181Be244D | 0.312 | |||
| 2009 | Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4619-29. PMID 19667279 DOI: 10.1200/Jco.2008.17.2775 | 0.334 | |||
| 2009 | He J, Makey D, Fojo T, Adams KT, Havekes B, Eisenhofer G, Sullivan P, Lai EW, Pacak K. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine. 36: 189-93. PMID 19618298 DOI: 10.1007/S12020-009-9219-6 | 0.317 | |||
| 2009 | Komlodi-Pasztor E, Trostel S, Sackett D, Poruchynsky M, Fojo T. Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells. Oncogene. 28: 3111-20. PMID 19581934 DOI: 10.1038/Onc.2009.166 | 0.313 | |||
| 2009 | Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. Journal of the National Cancer Institute. 101: 1044-8. PMID 19564563 DOI: 10.1093/Jnci/Djp177 | 0.322 | |||
| 2008 | Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, Fojo T, Oetting A, Gong J, Yen PM. A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Molecular Cancer Therapeutics. 7: 3719-28. PMID 19074847 DOI: 10.1158/1535-7163.Mct-08-0499 | 0.352 | |||
| 2008 | Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer--a recurring controversy. The Journal of Clinical Endocrinology and Metabolism. 93: 3730-2. PMID 18842984 DOI: 10.1210/Jc.2008-0579 | 0.356 | |||
| 2008 | Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. The Oncologist. 13: 1046-54. PMID 18838440 DOI: 10.1634/Theoncologist.2008-0075 | 0.343 | |||
| 2008 | Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. The Oncologist. 13: 1055-62. PMID 18827177 DOI: 10.1634/Theoncologist.2008-0016 | 0.339 | |||
| 2008 | Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle (Georgetown, Tex.). 7: 940-9. PMID 18414063 DOI: 10.4161/Cc.7.7.5625 | 0.343 | |||
| 2008 | Fojo T. Commentary: Novel therapies for cancer: why dirty might be better. The Oncologist. 13: 277-83. PMID 18378537 DOI: 10.1634/Theoncologist.2007-0090 | 0.318 | |||
| 2008 | Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? Journal of the National Cancer Institute. 100: 240-2. PMID 18270340 DOI: 10.1093/Jnci/Djm324 | 0.311 | |||
| 2008 | Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochemical Pharmacology. 75: 1302-12. PMID 18234154 DOI: 10.1016/J.Bcp.2007.12.001 | 0.354 | |||
| 2007 | Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7480-6. PMID 18094432 DOI: 10.1158/1078-0432.Ccr-06-2883 | 0.32 | |||
| 2007 | Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7280-7. PMID 18094408 DOI: 10.1158/1078-0432.Ccr-07-2141 | 0.359 | |||
| 2007 | Stein WD, Litman T, Fojo T, Bates SE. A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients. Biochimica Et Biophysica Acta. 1770: 857-71. PMID 17398010 DOI: 10.1016/J.Bbagen.2006.12.013 | 0.359 | |||
| 2007 | Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 10: 59-67. PMID 17350322 DOI: 10.1016/J.Drup.2007.02.002 | 0.365 | |||
| 2007 | Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Molecular Cancer Therapeutics. 6: 496-505. PMID 17308048 DOI: 10.1158/1535-7163.Mct-06-0431 | 0.32 | |||
| 2007 | Piekarz R, Frye R, Wright J, Figg W, Allen S, Kirschbaum M, Zain J, Hutchins L, Showe L, Fojo T, Bates SE. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma Journal of Clinical Oncology. 25: 8027-8027. DOI: 10.1200/Jco.2007.25.18_Suppl.8027 | 0.364 | |||
| 2006 | Huff LM, Lee JS, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. The Journal of Biological Chemistry. 281: 36501-9. PMID 16956878 DOI: 10.1074/Jbc.M602998200 | 0.359 | |||
| 2006 | Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3762-73. PMID 16778104 DOI: 10.1158/1078-0432.Ccr-05-2095 | 0.309 | |||
| 2006 | Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1547-55. PMID 16533780 DOI: 10.1158/1078-0432.Ccr-05-1423 | 0.398 | |||
| 2006 | Piekarz RL, Frye R, Turner M, Wright J, Allen S, Kirschbaum MH, Zain J, Prince M, Hutchins L, Showe LC, Figg WD, Fojo T, Bates SE. Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. Blood. 108: 2469-2469. DOI: 10.1182/Blood.V108.11.2469.2469 | 0.37 | |||
| 2006 | Goldsmith ME, Steadman K, Aguila A, Alley MC, Waud WR, Bates S, Fojo T. 294. The Histone Deacetylase Inhibitor FK228 Increases Histone Acetylation, Coxsackie Adenovirus Receptor Levels and Adenovirus Transgene Expression in Human LOX IMVI Melanoma Xenografts Molecular Therapy. 13: S112. DOI: 10.1016/J.Ymthe.2006.08.349 | 0.318 | |||
| 2005 | Widemann BC, Fox E, Goodspeed WJ, Goodwin A, Cohen M, Fojo T, Colevas AD, Balis FM. Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8529. PMID 27944613 DOI: 10.1200/Jco.2005.23.16_Suppl.8529 | 0.308 | |||
| 2005 | Huff LM, Wang Z, Iglesias A, Fojo T, Lee JS. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Research. 65: 11694-703. PMID 16357181 DOI: 10.1158/0008-5472.Can-04-1349 | 0.369 | |||
| 2005 | Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Research. 65: 9388-97. PMID 16230402 DOI: 10.1158/0008-5472.Can-04-4133 | 0.529 | |||
| 2005 | Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Research. 65: 7386-92. PMID 16103091 DOI: 10.1158/0008-5472.Can-04-3433 | 0.334 | |||
| 2005 | Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T. The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. Mutation Research. 583: 105-19. PMID 15927870 DOI: 10.1016/J.Mrgentox.2005.01.013 | 0.363 | |||
| 2005 | Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2726-34. PMID 15837987 DOI: 10.1200/Jco.2005.10.024 | 0.318 | |||
| 2005 | Demidenko ZN, Fojo T, Blagosklonny MV. Complementation of two mutant p53: implications for loss of heterozygosity in cancer. Febs Letters. 579: 2231-5. PMID 15811347 DOI: 10.1016/J.Febslet.2005.03.012 | 0.316 | |||
| 2005 | Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature Reviews. Cancer. 5: 275-84. PMID 15803154 DOI: 10.1038/Nrc1590 | 0.348 | |||
| 2005 | Neeman Z, Sarin S, Coleman J, Fojo T, Wood BJ. Radiofrequency ablation for tumor-related massive hematuria. Journal of Vascular and Interventional Radiology : Jvir. 16: 417-21. PMID 15758142 DOI: 10.1097/01.Rvi.0000147076.02176.13 | 0.311 | |||
| 2005 | Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Critical Reviews in Oncology/Hematology. 53: 25-34. PMID 15607933 DOI: 10.1016/J.Critrevonc.2004.09.008 | 0.353 | |||
| 2005 | Stein WD, Litman T, Fojo T, Bates SE. Differential expression of cell adhesion genes: implications for drug resistance. International Journal of Cancer. Journal International Du Cancer. 113: 861-5. PMID 15514970 DOI: 10.1002/Ijc.20671 | 0.397 | |||
| 2005 | Goldsmith ME, Aguila A, Alley MC, Waud WR, Bates S, Fojo T. 453. The Histone Deacetylase Inhibitor FK228 Can Increase Adenovirus Transgene Protein Expression in Human LOX IMVI Melanoma Xenografts Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.461 | 0.321 | |||
| 2004 | Low JA, Wedam SB, Brufsky A, Berman A, Croarkin E, Parks R, Steinberg SM, Mannan N, Fojo T, Swain SM. A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 545. PMID 28016592 DOI: 10.1200/Jco.2004.22.14_Suppl.545 | 0.314 | |||
| 2004 | Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry. 43: 13944-54. PMID 15518543 DOI: 10.1021/Bi049300+ | 0.314 | |||
| 2004 | Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, ... ... Fojo T, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4724-33. PMID 15269145 DOI: 10.1158/1078-0432.Ccr-0829-03 | 0.388 | |||
| 2004 | Mani S, Macapinlac M, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D. The clinical development of new mitotic inhibitors that stabilize the microtubule Anti-Cancer Drugs. 15: 553-558. PMID 15205596 DOI: 10.1097/01.Cad.0000131681.21637.B2 | 0.377 | |||
| 2004 | Stein WD, Litman T, Fojo T, Bates SE. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Research. 64: 2805-16. PMID 15087397 DOI: 10.1158/0008-5472.Can-03-3383 | 0.396 | |||
| 2004 | Zhuang SH, Menefee M, Kotz H, Agrawal M, Poruchynsky M, Hung E, Zhan Z, Linehan WM, Bates SE, Fojo T. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer Journal of Clinical Oncology. 22: 4550-4550. DOI: 10.1200/Jco.2004.22.90140.4550 | 0.397 | |||
| 2004 | Aguila A, Goldsmith ME, Gollapalli SJ, Alley MC, Waud WW, Bates S, Fojo T. 618. Coxsackie-Adenovirus Receptor (CAR) Levels Can Be Increased in Human Xenografts Followed by Treatment with FK228, a Histone Deacetylase Inhibitor Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.542 | 0.332 | |||
| 2003 | Fojo T, Bates S. Strategies for reversing drug resistance Oncogene. 22: 7512-7523. PMID 14576855 DOI: 10.1038/Sj.Onc.1206951 | 0.389 | |||
| 2003 | Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. The Oncologist. 8: 411-24. PMID 14530494 DOI: 10.1634/Theoncologist.8-5-411 | 0.416 | |||
| 2002 | Fojo T. p53 as a therapeutic target: Unresolved issues on the road to cancer therapy targeting mutant p53 Drug Resistance Updates. 5: 209-216. PMID 12450786 DOI: 10.1016/S1368-7646(02)00119-X | 0.385 | |||
| 2002 | Altaha R, Fojo T, Reed E, Abraham J. Epothilones: A novel class of non-taxane microtubule-stabilizing agents Current Pharmaceutical Design. 8: 1707-1712. PMID 12171542 DOI: 10.2174/1381612023394043 | 0.351 | |||
| 2002 | Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF, Fojo T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics Proceedings of the National Academy of Sciences of the United States of America. 99: 10855-10860. PMID 12145320 DOI: 10.1073/Pnas.132275599 | 0.302 | |||
| 2002 | Kitazono M, Chuman Y, Aikou T, Fojo T. Adenovirus HSV-TK construct with thyroid-specific promoter: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway International Journal of Cancer. 99: 453-459. PMID 11992417 DOI: 10.1002/Ijc.10307 | 0.356 | |||
| 2002 | Bates SE, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: Lessons from clinical oncology Novartis Foundation Symposium. 243: 83-102. PMID 11990784 DOI: 10.1002/0470846356.Ch7 | 0.378 | |||
| 2002 | Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV. The histone deacetylase inhibitor FR901228 (depsipeptide) restores expression and function of pseudo-null p53 Cancer Biology and Therapy. 1: 665-668. DOI: 10.4161/Cbt.317 | 0.329 | |||
| 2002 | Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters Nature Reviews Cancer. 2: 48-58. DOI: 10.1038/Nrc706 | 0.389 | |||
| 2001 | Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (Valspodar) Cancer. 92: 1577-1590. PMID 11745237 DOI: 10.1002/1097-0142(20010915)92:6<1577::Aid-Cncr1484>3.0.Co;2-H | 0.314 | |||
| 2001 | Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochemical Pharmacology. 62: 1469-80. PMID 11728383 DOI: 10.1016/S0006-2952(01)00804-8 | 0.384 | |||
| 2001 | Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase IIα mRNA of etoposide and mAMSA-resistant cell lines Japanese Journal of Cancer Research. 92: 1133-1137. PMID 11676865 DOI: 10.1111/J.1349-7006.2001.Tb01069.X | 0.355 | |||
| 2001 | Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15: 1537-43. PMID 11587211 DOI: 10.1038/Sj.Leu.2402257 | 0.322 | |||
| 2001 | Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy Journal of the National Cancer Institute. 93: 1434-1436. PMID 11584051 DOI: 10.1093/Jnci/93.19.1434 | 0.316 | |||
| 2001 | Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells Japanese Journal of Cancer Research. 92: 778-884. PMID 11473729 DOI: 10.1111/J.1349-7006.2001.Tb01161.X | 0.351 | |||
| 2001 | Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the NA+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism. 86: 3430-3435. PMID 11443220 DOI: 10.1210/Jcem.86.7.7621 | 0.31 | |||
| 2001 | Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity Oncogene. 20: 3806-3813. PMID 11439344 DOI: 10.1038/Sj.Onc.1204487 | 0.322 | |||
| 2001 | Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM, Bachenheimer L, Abraham J, Wood BJ. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. Journal of the National Cancer Institute. 93: 648-9. PMID 11309443 DOI: 10.1093/Jnci/93.8.648 | 0.3 | |||
| 2001 | Nicoletti MI, Myers TG, Fojo T, Blagosklonny MV. Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells International Journal of Oncology. 18: 375-381. PMID 11172607 DOI: 10.3892/Ijo.18.2.375 | 0.349 | |||
| 2001 | Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism. 86: 834-840. PMID 11158054 DOI: 10.1210/Jcem.86.2.7196 | 0.327 | |||
| 2001 | Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833 Journal of Clinical Oncology. 19: 832-842. PMID 11157037 DOI: 10.1200/Jco.2001.19.3.832 | 0.316 | |||
| 2001 | Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Hypophosphorylation of topoisomerase IIα in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation Japanese Journal of Cancer Research. 92: 799-805. DOI: 10.1111/J.1349-7006.2001.Tb01164.X | 0.351 | |||
| 2000 | Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 19: 3078-85. PMID 10871860 DOI: 10.1038/Sj.Onc.1203642 | 0.379 | |||
| 2000 | Harada T, Nagayama J, Kohno K, Mickley LA, Fojo T, Kuwano M, Wada M. Alu-associated interstitial deletions and chromosomal re-arrangement in 2 human multidrug-resistant cell lines. International Journal of Cancer. 86: 506-11. PMID 10797263 DOI: 10.1002/(Sici)1097-0215(20000515)86:4<506::Aid-Ijc10>3.0.Co;2-8 | 0.32 | |||
| 2000 | Vandier D, Calvez V, Massade L, Gouyette A, Mickley L, Fojo T, Rixe O. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. Journal of the National Cancer Institute. 92: 642-7. PMID 10772682 DOI: 10.1093/Jnci/92.8.642 | 0.38 | |||
| 2000 | Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 2904-9. PMID 10688884 DOI: 10.1073/Pnas.040546297 | 0.326 | |||
| 2000 | Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. The Journal of Clinical Investigation. 105: 533-9. PMID 10683383 DOI: 10.1172/Jci8625 | 0.364 | |||
| 2000 | Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. Journal of the National Cancer Institute. 92: 182-3. PMID 10655426 DOI: 10.1093/Jnci/92.3.182 | 0.359 | |||
| 2000 | Chuman Y, Zhan Z, Fojo T. Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway Journal of Clinical Endocrinology and Metabolism. 85: 253-262. PMID 10634396 DOI: 10.1210/Jcem.85.1.6244 | 0.343 | |||
| 1999 | Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). International Journal of Cancer. 83: 151-6. PMID 10471519 DOI: 10.1002/(Sici)1097-0215(19991008)83:2<151::Aid-Ijc1>3.0.Co;2-5 | 0.399 | |||
| 1999 | Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S. Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833 Blood. 93: 306-314. DOI: 10.1182/Blood.V93.1.306.401K42_306_314 | 0.328 | |||
| 1998 | Sandor V, Fojo T, Bates SE. Future perspectives for the development of P-glycoprotein modulators. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 1: 190-200. PMID 17092805 DOI: 10.1016/S1368-7646(98)80039-3 | 0.408 | |||
| 1998 | Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, Fojo T. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Molecular Pharmacology. 54: 802-14. PMID 9804615 DOI: 10.1124/Mol.54.5.802 | 0.358 | |||
| 1998 | An WG, Chuman Y, Fojo T, Blagosklonny MV. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Experimental Cell Research. 244: 54-60. PMID 9770348 DOI: 10.1006/Excr.1998.4193 | 0.305 | |||
| 1998 | Knutsen T, Mickley LA, Ried T, Green ED, du Manoir S, Schröck E, Macville M, Ning Y, Robey R, Polymeropoulos M, Torres R, Fojo T. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes, Chromosomes & Cancer. 23: 44-54. PMID 9713996 DOI: 10.1002/(Sici)1098-2264(199809)23:1<44::Aid-Gcc7>3.0.Co;2-6 | 0.352 | |||
| 1998 | Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. The Journal of Clinical Endocrinology and Metabolism. 83: 2516-22. PMID 9661637 DOI: 10.1210/Jcem.83.7.4984 | 0.342 | |||
| 1998 | Blagosklonny MV, Iglesias A, Zhan Z, Fojo T. Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. Biochemical and Biophysical Research Communications. 244: 368-73. PMID 9514935 DOI: 10.1006/Bbrc.1998.8278 | 0.322 | |||
| 1998 | Sandor V, Wilson W, Fojo T, Bates SE. The role of MDR-1 in refractory lymphoma. Leukemia & Lymphoma. 28: 23-31. PMID 9498700 DOI: 10.3109/10428199709058327 | 0.373 | |||
| 1998 | Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. International Journal of Cancer. 75: 57-63. PMID 9426691 DOI: 10.1002/(Sici)1097-0215(19980105)75:1<57::Aid-Ijc10>3.0.Co;2-A | 0.363 | |||
| 1998 | Mickley LA, Lee J, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors Blood. 91: 1749-1756. DOI: 10.1182/Blood.V91.5.1749.1749_1749_1756 | 0.339 | |||
| 1997 | Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of Biological Chemistry. 272: 17118-25. PMID 9202030 DOI: 10.1074/Jbc.272.27.17118 | 0.356 | |||
| 1997 | Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. The Journal of Clinical Investigation. 99: 1947-57. PMID 9109439 DOI: 10.1172/Jci119362 | 0.326 | |||
| 1997 | Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Van Osdol WW, Monks AP, Scudiero DA, Sausville EA, et al. An information-intensive approach to the molecular pharmacology of cancer Science. 275: 343-349. PMID 8994024 DOI: 10.1126/Science.275.5298.343 | 0.373 | |||
| 1997 | Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochemical Pharmacology. 52: 1855-65. PMID 8951344 DOI: 10.1016/S0006-2952(97)81490-6 | 0.375 | |||
| 1996 | Barnes KM, Dickstein B, Cutler GB, Fojo T, Bates SE. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 35: 4820-7. PMID 8664272 DOI: 10.1021/Bi952380K | 0.357 | |||
| 1995 | Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. The Journal of Clinical Investigation. 95: 2205-14. PMID 7738186 DOI: 10.1172/Jci117910 | 0.422 | |||
| 1994 | Bates S, Wilson W, Fojo T, Wittes R, Bryant G, Chabner B. R-verapamil reverses drug resistance in some relapsed lymphoma patients Anti-Cancer Drugs. 5: 72. DOI: 10.1097/00001813-199409001-00165 | 0.312 | |||
| 1994 | Fojo T, Mickley L, Bates S, Wilson W, Zhan Z. Detection of MDR1 alleles and acquired mutations as tools for understanding expression of MDR1 in drug selected cell lines and human cancers Anti-Cancer Drugs. 5: 70. DOI: 10.1097/00001813-199409001-00160 | 0.348 | |||
| Show low-probability matches. | |||||